Podcasts about HIV

Hoch die Hände, Wochenende – mit einer geballten Ladung guter Nachrichten, diesmal auch in eigener Sache: Vor ziemlich genau fünf Jahren, im Februar 2021, haben wir diesen Podcast unter unseren Bettdecken gestartet (ja, wirklich, für die Tonqualität). Inzwischen ist er nach über 250 Folgen seinen Babyschuhen entwachsen und feiert seinen fünften Geburtstag. Auf viele mehr! Das Schönste: Er macht offenbar nicht nur mir Freude, sondern auch Tausenden von Hörer:innen. Und jetzt, zum kleinen Jubiläum, wage ich eine schelmische Wette: Wetten, unser Podcast gewinnt durch diese kleine Nachricht 1.000 neue Hörer:innen? Top, die Wette gilt! Dänemark stoppt HIV-Übertragung von Mutter zu Kind https://www1.wdr.de/mediathek/audio/cosmo/daily-good-news/audio-daenemark-stoppt-hiv-uebertragung-100.html#:~:text=Verf%C3%BCgbar%20bis%2002.03.2027,Schwangerschaft%20auf%20das%20Kind%20eliminiert. Kroatien erklärt sich nach Jahrzehnten für minenfrei https://www.mdr.de/nachrichten/welt/osteuropa/politik/kroatien-landminen-100.html Großprojekt soll Sepsis-Versorgung in Deutschland revolutionieren https://www.mdr.de/wissen/medizin-gesundheit/blutvergiftung-sepsis-tote-krankenhaeuser-universitaetsmedizin-leipzig-100.html Schutzprojekt bei Mainz lässt Feldhamster zurückkehren https://www.stern.de/gesellschaft/regional/rheinland-pfalz-saarland/artenschutz--wieder-mehr-feldhamster---schutzprojekt-laeuft-weiter-37184662.html „Good News: der Podcast für gute Nachrichten“ ist ein Podcast von Good News und Good Impact. Aufnahme und Redaktion: Bianca Kriel Dir gefällt, was wir tun? Werde Good Member! Für 5 Euro im Monat bekommst du die geballte Ladung gute Nachrichten und konstruktive Geschichten. https://steadyhq.com/de/good-membership/about?utm_medium=podcast&utm_source=link&utm_campaign=shownotes&utm_content=good-impact Hier findest du das aktuelle Good Impact Magazin “Jetzt erst recht. Inspirationen für eine sprühende Zukunft”: https://www.goodbuy.eu/products/16-jetzt-erst-recht Good News ist spendenbasiert, wenn dir unsere Arbeit und dieser Podcast gefallen, kannst du uns hier unterstützen, Vermerk “Podcast”: https://donorbox.org/good-news-app Mehr Good News bekommst du hier: https://goodnews.eu/ Kontakt: redaktion@goodnews.eu

Program notes:0:37 HIV treatment monthly injections1:37 Long acting and effective2:37 Some didn't come for monthly injections3:16 COVID-19 vaccination and preeclampsia rate4:16 In two successive cohorts during pandemic5:16 Pre-existing morbidity 58% reduction6:15 COVID-19 cytokine storm?6:45 Monkeypox treatment7:45 Randomized to placebo or smallpox drug8:50 Menstrual blood to test for HPV9:50 Minipad essentially the same as clinician collection10:45 Can make it cost effective?11:49 End

This week, Marianna sits down with John Faragon to talk about injectable PrEP and drug interactions. Tune in to learn about the current options for injectable PrEP, how the medications are metabolized, and more. -- Resources mentioned in this episode: NECA AETC Mobile Apps: https://www.necaaetc.org/mobile-appsHIV ART Drug Interactions Guidelines: https://www.hivguidelines.org/guideline/hiv-art-drug-interactions/HIV Drug Interactions Checker: https://www.hiv-druginteractions.org/checker--Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

Drawing on her landmark work in HIV and vaccine research, Glenda Gray shares powerful lessons for tackling AMR in this last deep dive episode. From prevention and behavioural science to protecting high-risk populations, she explains how strategies that transformed HIV outcomes can inform a more effective and equitable AMR response. Timestamps: 00:00 – Introduction 01:02 – Lessons from HIV 02:47 – Vaccine trials 03:50 – AMR interventions 05:17 – Behavioural science 06:31 – Key takeaways

On today's episode of The Therapy Crouch, things get steamy (and seriously educational) as Abbey and Peter are joined by renowned sex educator, journalist and PhD researcher Alix Fox.Alix has spent over two decades exploring the ins and outs (quite literally) of intimacy, fetishes and modern relationships. From her early days reporting on BDSM and subcultures, to working as a script consultant on Netflix's Sex Education, and now completing a PhD at UCL focused on HIV prevention — Alix has seen every side of the conversation when it comes to sex.The trio dive into everything from the rise in fantasy-inspired sex toys (up 244% this year!), to why more than half of women admit to faking orgasms to protect their partner's feelings. They discuss the stigma straight men still face around sex toys, how to introduce fantasies into long-term relationships without offending your partner, and whether honesty in the bedroom is always the best policy.There are jaw-dropping sex disaster stories (including a frozen sausage incident you will never unhear), eye-opening insights into menopause and libido, and practical advice for couples who want to reset their expectations without hurting feelings.It's funny, shocking, awkward and genuinely informative — and it might just change the way you think about your sex life. Hosted on Acast. See acast.com/privacy for more information.

This month on JHLT: The Podcast, the Digital Media Editors host two themed discussions around HIV in solid organ transplantation. The conversation begins with a discussion of the paper, "Early experience in heart transplantation utilizing donors with HIV," which appears in the March issue of JHLT. First author Omar Saeed, MD, MSc, of the Division of Cardiology at Montefiore Medical Center in New York, NY USA, joins the episode. The conversation includes discussion of: The ethics and evolution of the Montefiore program's transplant eligibility and criteria The role of the HOPE Act in the changes to the program Superinfection, viral strain analysis, and informed consent of organ recipients Long-term patient follow upsa nd how other centers can begin this research For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Return later this month for a broader conversation with an infectious diseases expert about HIV in transplantation. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Heather and Jonny commiserate over the eruption og globala military actions and the controversyies around the Trump Administrations actions and (lack of) explanations. They posit the role of conflict in controling and manipulating others. They then take this theme of x vs. y to other conflicts recently impacting the LGBTQ+ community, some further illuminating the US vs. Iran conflict eclipsing all others at the moment.

Aging reshapes the immune system in two fundamental ways: it alters the proportions of different immune cell types circulating in the blood, and it induces molecular changes within each individual cell. For years, researchers have struggled to disentangle these two intertwined processes using standard “bulk” measurements, which average signals across millions of cells and obscure what is happening at the single-cell level. A new research paper, titled “Single-cell transcriptomics reveal intrinsic and systemic T cell aging in COVID-19 and HIV” published in Volume 18 of Aging-US by researchers at the Buck Institute for Research on Aging in California, the University of Southern California, and the University of Copenhagen, introduces an innovative solution. The team of Alan Tomusiak, Sierra Lore, Morten Scheibye-Knudsen, and corresponding author Eric Verdin, developed a novel tool called Tictock (T immune cell transcriptomic clock) that uses single-cell RNA sequencing to separately measure systemic and cell-intrinsic components of immune aging, and then applied it to understand how COVID-19 and HIV affect T cells. Full blog - https://aging-us.org/2026/03/tictock-a-single-cell-clock-measures-immune-aging-in-viral-infections/ Paper DOI - https://doi.org/10.18632/aging.206353 Corresponding author - Eric Verdin - EVerdin@buckinstitute.org Abstract video - https://www.youtube.com/watch?v=_r3AF7OrgKY Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206353 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, transcriptomic clock, aging biomarkers, systemic aging, intrinsic aging To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Ria Spencer, Mindy Myers and Josh Connors share stories about learning to feel at home in your body.

Tuesday, March 3rd, 2026 Today, The Hennepin County DA is criminally investigating Gregory Bovino and others actions during Operation Metro Surge; the House Oversight Committee has released the video depositions of Bill and Hillary Clinton; Florida has cut off 12,000 people from receiving their HIV medication; Scouting America abandons its DEI policies under an agreement with the Pentagon; the DOJ examined 7 men in an Epstein probe but none were charged; and Allison and Dana read your Good News; and Allison and Dana read your Good News. Thank You, IQBAR Text DAILYBEANS to 64000 to get 20% off all IQBAR products, plus FREE shipping. Message and data rates may apply.    Dana is on Patreon! At Dana's Dugoutpatreon.com/cw/dgcomedy The LatestProject Salt Box | muellershewrote StoriesGreg Bovino, other federal agents investigated for Operation Metro Surge actions | Minnesota Star Tribune Florida suddenly cuts off 12,000 people from receiving their HIV meds | Advocate.com DOJ Examined Men in Epstein's Orbit Accused of Sex Crimes. None Were Charged. | WSJ Scouts Will Abandon D.E.I. Policies Under Agreement With Pentagon, Hegseth Says | The New York Times Good TroubleStop Unauthorized Military Strikes on Iran - 5 Calls The United States and Israel have launched “major combat operations” in Iran. At least 6 US Troops and Hundreds of civilians have been killed. Trump unilaterally engaged our military without the constitutionally required congressional authorization. Demand your representatives support the bipartisan war powers resolution to rein in Trump's reckless use of our military.Find Your Representative | house.govContacting U.S. Senators   →Public Comment Period Open: White House Ballroom Proposal →Standwithminnesota.com →Tell Congress Ice out Now | Indivisible →Defund ICE | 5Calls →Congress: Divest From ICE and CBP | ACLU →ICE List  →iceout.org →2026 Trans Girl Scouts To Order Cookies From! | Erin in the Morning Good News Beans Talk audio -beans-talk.simplecast.comcindilynch.substack.com Lawrence Hopewell Trail GLAAD Media Awards →Share your Good News & Good Trouble - The Daily Beans Subscribe to the MSW YouTube Channel - MSW Media - YouTube Our Donation Links Pathways to Citizenship link to MATCH Allison's Donationhttps://crm.bloomerang.co/HostedDonation?ApiKey=pub_86ff5236-dd26-11ec-b5ee-066e3d38bc77&WidgetId=6388736 Allison is donating $20K to It Gets Better and inviting you to help match her donations. Your support makes this work possible, Daily Beans fam. Donate to It Gets Better / The Daily Beans Fundraiser Join Dana and The Daily Beans with a MATCHED Donation http://onecau.se/_ekes71 More Donation LinksNational Security Counselors - Donate

Dr. Deb Muth 0:00 Welcome back to Let’s Talk Wellness Now. I’m your host, Dr. Zab, and we are continuing our discussion this week on 0:08 peptides. And so, if you haven’t heard our first conversation about peptides, 0:13 please go back and look at that episode. We talk all about the manufacturing, the safety, the quality of peptides, and we 0:20 dove into GLP1s. And today we’re going to dive into peptides for sexual 0:26 wellness, immune function, growth hormone, and all the amazing fun things 0:32 we can do with peptides. So, as usual, grab your cup of coffee or tea, settle 0:37 in, and let’s talk wellness now. And we’re going to take a short pause from our sponsor. I know we’ve got to do 0:44 that, you guys. They’re who keep us on the air. So, I’m going to pause for just a minute and be right back after this 0:50 message from our sponsor. Ladies, it’s time to reignite your vitality. Primal 0:56 Queen supplements are clean, powerful formulas made for women like you who want balance, strength, and energy that 1:03 lasts. Get 25% off at primal queen.com. Serenity Health. That’s primalqueen.com. 1:10 Serenity Health. Because every queen deserves to feel in her prime. All 1:15 right, everybody. We are back. And are you ready? We are talking all things peptide and I am opening the show today 1:23 with sexual wellness. Yes, I’m going there, you guys. I am going there. You 1:29 know, this has really become a big issue for people um of all ages. It’s not just 1:3 4us older people. It’s younger people, too. And there’s a whole variety of reasons why we have sexual dysfunction. 1:42 And when we’re talking about sexual dysfunction, we’re not just talking about it doesn’t work, right? Or I can’t 1:48 reach orgasm. A lot of it is around desire and um the thought of it and 1:54 wanting to connect, wanting to be kinder to one another, wanting to be touching 2:00 one another. A lot of it resolves or revolves around that. And so there are some peptides that can help us and I’m 2:08 really excited to be able to talk about those today. So the first one is called PT-141. 2:14 This targets the brain not the periphery. Right? So for many women I 2:20 will always tell you sex starts between here. It is a brain thing for us. It is 2:26 not necessarily a physical thing. For guys that’s a little different. It’s very physical. For women it’s all in our 2:32 brain. So tip for you men that are listening. You have to prime your woman’s brain first if you want her to 2:38 have sex with you that night. You have to be nice to her. You have to bring her flowers. Do the dishes for her. Do 2:45 something kind. Bring her a cup of coffee or tea or a glass of wine. Take her to dinner. You have to woo her. And 2:51 I don’t care how long you’ve been married. That has to happen. And tip number two, don’t say anything stupid 2:57 that day. I’m just being honest. When you guys say things that make us upset, 3:03 that lingers with us for the rest of the day. And it’s it’s a turnoff for us. And 3:08 for a lot of women, we can’t get past that when it comes time to snuggle at night. And sex doesn’t always have to be 3:14 at night either. So, you can tell I really love talking about this conversation, but we’re going to get into the peptide part of it because this 3:21 is going to help people. So, um, PT-141 is marketed as I’m going to slaughter 3:28 this name, Vali, and it represents a fundamentally different approach to 3:34 sexual dysfunction than the PDE5s inhibitors like Slenden, Viagra, 3:40 Tedataphil, which is Seialis. And while the PDE5 inhibitors work specifically by 3:47 enhancing blood flow to the genital tissues, PT-141 works centrally in the brain by 3:54 modulating neural s neural circuits involved in the sexual desire and 4:00 arousal. Now PT-41 is a cyclic hpatipeptide. It’s seven amino acid 4:07 peptide arranged in a cyclic structure that acts as a melanoortin receptor 4:13 agonist and with particularly the infinity for MC3R and MC4R subtypes. 4:20 It’s actually a metabolite of the melanotan 2, a peptide originally 4:26 developed for tanning that was also found to enhance sexual desire in early 4:31 studies. Now the melanoortin system in the brain is involved in multiple functions including energy homeostasis 4:39 but it also is involved in sexual motivation and arousal behaviors. The FDA approved PT-141 in 2019 specifically 4:48 for the treatment of acquired generalized hypoactive sexual desire 4:54 HSDD in permenopausal women. So for the first time we have a medication that was 5:01 approved by the FDA to use for women for sexual dysfunction. We have had all of 5:07 these seialis tedataphil viagros for men but we had nothing for women. And so 5:12 this is amazing that this is available for women and approved by the FDA. It’s a big deal. This represents the first 5:19 and only FDA approved medication specifically targeting these circuits of sexual desire rather than the peripheral 5:27 arousal mechanisms. And this indication is quite specific, meaning it was developed at some point, not lifelong. 5:35 So I if you’ve had sexual dysfunction your entire life, this medication was 5:40 not approved for you. But if it’s something that you developed over time, like when you went through pmenopause or 5:46 menopause or some women have this experience happen after childirth, that’s what we’re talking about here. 5:53 Now, it’s also not just um supposed to be used if you dislike your partner, 5:59 right? If your relationship is bad and you dislike your partner, this probably isn’t going to fix a ton. It might help 6:05 a little bit, but that’s not what it’s meant for. So, you really have to know what you’re using it for and why. And 6:11 the other thing that I would say is this is something that we don’t go to if your hormones are not balanced properly. You 6:17 have to balance your hormones properly before using something like this because it still may not work. Now, the only 6:24 caveat to that is if you’re a woman that has a risk of breast cancer and can’t use hormones, then that’s a different 6:31 story and we would have that conversation about whether or not this medication would be appropriate for you. Now, the FDA label specifies PTA1 uh 6:39 PT-141 as it not being indicated for HSDD in causes where low sexual desire 6:46 is due to coexisting medical or psychiatric conditions, problems with relationships, like we had talked about, 6:53 side effects to medications or other substance use. This specifically reflects the importance of differential 6:59 diagnosis. Low sexual desire can have many root causes and PT-41 is only 7:05 appropriate when those causes have been ruled out. Now, I have I used PT41 in 7:10 people who have sexual dysfunction issues as a result of using 7:16 anti-depressants. Yes, I have. I’ve used Flynn in that effect as well. And it 7:21 does work sometimes, but it doesn’t work completely. But you need to know that that is not what the approval is for the 7:27 FDA. So that is done in something that we call off label use. So very important 7:33 to know. Now in these clinical trials leading to FDA approval, this was published by Kinsburg and colleagues in 7:40 obstetrics and gyne gynecology in 2019. PT-141 demonstrated statistically 7:46 significant improvements in sexual desire and decreases in distress related 7:51 to low desire compared to placebo. The effects manifest over 45 minutes to 7:56 several hours after the injection and the mechanisms involved modulation of dopamine and melanoorton pathways in the 8:04 hypothalamus and the brain regions that involved sexual motivation. Now cardiovascular effects of PT 141 require 8:12 careful attention. This drug causes transient increases in blood pressure about 3 to four points and transient 8:20 decreases in heart rate. And because of this, it is contraindicated in patients 8:25 with uncontrolled hypertension or known cardiovascular disease. And it has been studied in patients who’ve had recent 8:32 cardiovascular events or sorry hasn’t been studied hasn’t been studied in patients who’ve had recent 8:39 cardiovascular events. So patients need to have their blood pressures checked before starting therapy. Nausea is 8:45 extremely common. It is one of the biggest things I often will tell people to take an anti-nausea medicine if 8:52 they’re going to do this because the last thing you want to do is inject this medication and think it’s going to give 8:57 you this great time with your partner and you’re so nauseated that you can’t even perform, don’t want to kiss, don’t 9:05 want to do anything. It it can be pretty profound for some people. um it does affect about 40% of the patients in 9:12 clinical trials which is why many clinicians require or recommend an 9:17 anti-nausea medication like I had just said other common adverse effects include flushing injection site 9:24 reactions headache in about 13% of the population which I have seen worse if 9:30 people are prone to headaches and the headaches are pretty intense so I will also have them premedicate if they have 9:36 that um sensitivity ity with a Tylenol or Advil, Alie, whatever it is they 9:42 typically use for their headaches to help prevent that from occurring. Now, some patients also experience a 9:50 generalized hyperpigmentation of their skin, particularly in areas with chronic friction, and this may not be reversible 9:57 after discontinuation. So from an integrative perspective, PT-41 10:03 represents one tool in addressing female sexual dysfunction, but it should never be the first or only intervention. And 10:11 low sexual desire in women is complex. Multiffactorial involving hormonal imbalances, low testosterone, estrogen 10:18 deficiency, progesterone imbalances, thyroid dysfunction, adrenal dysfunction, and with elevated or 10:24 disregulated cortisol levels, sleep deprivation, relationship issues, unresolved trauma, including sexual 10:31 trauma, chronic pain, body image concerns, and medication side effects such as SSRIs are notorious for this. So 10:39 a comprehensive hormone panel including total and free testosterones, estradile, 10:45 progesterone, DHEA, thyroid function in cortisol assessment, ideally four-point 10:51 cortisol, salivary should precede any pharmacological intervention. And additionally, addressing the 10:57 psychological component and relationship dimensions through appropriate therapy is necessary. I have a lot of patients 11:03 that say, “This is just too much work for sex. I don’t want the side effects. I don’t want to deal with this.” and that’s totally fine. But for some 11:09 people, their sexual dysfunction is actually causing more problems on their 11:14 relationship and they want to do something to fix that. And just know that if you’re using a peptide like this 11:20 that comes with some of these side effects and you have to premedicate for it, it is not the end of the world. Um, 11:27 but it may be a possibility that you may need that. So, let’s dive into body composition and growth hormone access. 11:34 So Tesmarellin is the only FDA approved GH 11:40 analog. Tesarelin is marketed as Agrifta and Agria SV. It is a synthetic analog 11:48 of human growth hormone releasing hormone. So GH RH human growth hormone 11:53 releasing hormone. These things are such long names it’s confusing and it’s difficult to spit out, right? It 11:59 consists of 44 amino acids. The structure is identical to our own 12:05 body’s growth hormone GHR um with the addition of trans3 hexonol group which 12:14 stabilizes the molecule that extends its half-life compared to the native GHR. 12:19 The mechanism of tesmarellin is elegant in its preservation of physiological 12:24 growth hormone GH secretion patterns and rather than administering an exogenous 12:30 growth hormone directly, tesmarillin binds to the GH receptor in the anterior 12:36 pituitary gland stimulating the indogenous pulsatile release of GH. So 12:42 you know it it’s slower in that stimulation and it pulsates instead of a direct rise and fall. This pusile 12:49 pattern more closely mimics natural GH secretion which occurs in bursts 12:54 primarily during sleep. The GH then stimulates the liver to produce insulin-like growth factor IGF-1 which 13:01 exerts many of the downstream metabolic effects including lipolytic effects on 13:07 the atapost tissue. So fat atapose and how we break that down. The FDA approved 13:13 tesmarellin in 2010 for a very specific narrow indication, the reduction of 13:19 excess abdominal fat in HIV infected patients with lipodistrophe. This 13:25 condition characterized by abnormal fat redistribution with accumulation of visceral body fat and the loss of 13:32 subcutaneous fat in face and limbs developed as a complication of an 13:37 antiviral therapy particularly with older protease inhibitor reg uh 13:42 regimens. The visceral fat accumulation in patients is not just cosmetic. It’s associated with increased cardiovascular 13:49 risk, insulin resistance, and inflammatory markers. The pivotal trial that led to the FDA approval included 13:56 work by Stanley and colleagues published in the annuals of internal medicine in 2014. It demonstrated that tesmarillan 14:03 significantly reduced the visceral atapose measured by CT scan by approximately 15 to 20% which is a 14:10 significant difference to placebo over a short period of time only 26 weeks. Now, 14:16 interestingly, the total body uh weight typically remained stable or even 14:21 increased slightly as the reduction of visceral fat was sometimes offset by increases in lean body mass or 14:28 subcutaneous fat. This highlights an important point. Tesmearellin is not a weight loss drug in its conventional 14:34 sense. Its effects are specifically on body composition and fat redistribution. 14:40 Now the glucose metabolism effects of tesmarellin do require careful monitoring because GH and IGF1 can 14:47 induce insulin resistance. Tesmearellin can increase glucose levels and hemoglobin A1C and in these clinical 14:54 trials glucose tolerance and new onset diabetes occurred in some patients. So 14:59 this creates a therapeutic paradox while res reducing visceral fat we should theoretically improve metabolic health. 15:07 The GH mediated insulin resistance can worsen the glycemic control and patients 15:12 with diabetes require particularly close monitoring. The potential need for adjustment in diabetic medications can 15:19 occur. So I already know what you guys are thinking. Can I use Tesmarellin and 15:24 GLP1 at the same time? And the answer is yes. Especially in those people that we 15:30 know have an insulin resistance already or are prone to that, we can use lowd 15:36 dose micro doing GLP-1 along with tesmarellin to help prevent this from 15:42 occurring um or reduce the risk of it occurring. Now there are some other adverse related problems to growth 15:49 hormone access which include fluid retention which can uh manifest as uh 15:55 ankle swelling, joint pain, muscle pain, paristhesas, carpal tunnel syndrome is 16:01 common to see. Of course you can always see injection site reactions reported about 26 to 30% of the time in the trial 16:08 participants. And this also theoretically has a concern about IGF-1 elevation potentially promoting 16:14 malignancy through long-term data is limited. So we have to be cautious about 16:20 this but it is a growth hormone and anything that is a growth hormone can cause cells to grow and it cannot 16:26 necessarily differentiate between healthy cells and bad cells. So the drug is contraindicated is contraindicated in 16:33 patients with active cancer and in patients with the disruption of the HPA access from conditions like pituitary 16:40 tumors, pituitary surgery, head of radiation um and traumatic brain injury. 16:46 Now off label use of tesmarellin for general anti-aging or body composition 16:51 optimization in non-HIV population, it doesn’t have FDA approval. There is no 16:58 FDA studies. um that promote this, but practitioners do prescribe it for these 17:04 purposes under an experimental and not supported by FDA approved indications. 17:10 And um from an integrative medical standpoint, optimizing natural growth 17:15 hormone secretion through lifestyle interventions, high quality sleep is important. GH primarily is excreted 17:22 during sleep and deep sleep waves. So improving your deep sleep is important. Intermittent fasting can also increase 17:28 growth hormone by five-fold as demonstrated in a Hartman and colleagues uh study from the journal of clinical 17:35 endocrinology and metabolism in 1992. And highintensity interval training, adequate dietary protein, blood sugar 17:42 control, these all can help naturally increase your growth hormone. So, let’s 17:47 dive in now and talk about bone health. peptide hormones um such as oh I’m gonna 17:54 I’m gonna really slaughter this name. Terraparatide is a true bonebuilding 18:01 peptide. It’s marketed as forio. It’s a recumbent form of the first 34 amino 18:08 acids out of 85 of the human parathyroid hormone PTH. It represents a unique 18:13 approach to osteoporosis treatment because it’s one of the few truly anabolic anabolic bone therapies meaning 18:21 it actively binds new bone rather than simply preventing bone loss. The biology 18:26 of parathyroid is fascinating and seemly contraindicated or uh contradictory. 18:32 Continuously sustained elevations of PTH as occurs in hyperarathyroidism 18:37 is catabolic to bone. So people who have hyperarothyroidism typically have significant bone loss 18:44 especially before it’s diagnosed and it causes causes increased bone 18:49 reabsorption loss of bone density increased fracture risk and however 18:55 intermittent exposure to PTH as achieved with once daily uh injections of forio 19:01 has the opposite effect. This intermittent exposure preferentially stimulates osteoblasts bone building 19:08 cells over osteoclasts bone reabsorbing cells and it leads to 19:13 the net bone formation. So terraparatide binds to the PTH receptors on 19:20 osteoblasts and renal tubular cells in bone. It increases the number of 19:25 activity of osteoblasts stimulating the differentiation of osteoblast precursor cells and may 19:32 reduce osteoblast apoptosis basically programmed cell death allowing this bone 19:37 building cell to work longer. The result is increased bone formation, improved bone architecture and tbacular 19:45 connectivity and ultimately increased bone mineral density um particularly in the hip and the spine which is so 19:51 difficult to regain. The FDA approved this medication in 2002 based on pivotal 19:57 studies by Near and colleagues published in the New England Journal of Medicine in 2001 which demonstrated significant 20:05 reductions in vertebral and non-vebral fractures in post-menopausal women with 20:11 osteoporosis. specifically uh reduced new vertebral fractures by 20:17 65% and nonvettebral fragility fractures by 53% 20:23 compared to placebo over a median followup of 21 months. This is really 20:29 incredible because we have not seen this kind of um change uh in other 20:35 medications that we’ve used for osteoporosis. So current FDA approval 20:40 indicates uh this for post-menopausal women with osteoporosis at high risk for 20:46 fracture, men with primary or hypoconatal osteoporosis at high risk for fracture 20:53 and men and women with glucocord cord glucocordide 21:00 induced osteoporosis at high risk for fracture. The high risk qualifier is 21:05 important. uh terrapeptide is reserved for patients with severe osteoporosis, 21:11 multiple fractures, very low low bone density and those who have failed or are 21:16 intolerant of other therapies. The most significant concern for this medication 21:21 is highlighted in a boxed warning with rat toxicology studies where it caused 21:27 osteioaroma which is a bone cancer in a dose dependent and treatment duration dependent manner. The revolence of this 21:34 finding to humans is debated. Rats have fundamentally different bone biology than humans with continuous bone growth 21:41 throughout life and different PTH receptors. Now post marketing 21:46 surveillance in humans hasn’t shown a clear increase in osteocaroma risk but 21:51 theoretically concerns persist and because of this terapeptide is 21:57 contraindicated in patients at risk baseline risk for osteioaroma 22:02 including those with pageantss disease of the bone unexplained elevations of alkaline phosphate prior skeletal 22:10 radiations bone metastases or skeletal malignancies and pediatric patients or young adults 22:16 with open hyes. There’s also a lifetime treatment duration of only 2 years and 22:22 terrapeptide can cause transient hypercalcemia. So an elevated blood calcium and as PTH normally increases 22:31 calcium levels by enhancing bone reabsorption, increasing renal calcium 22:36 reabsorption and promoting activation of vitamin D which increases intestinal calcium absorption. Some patients 22:43 experience orthostatic hypotension within 4 hours of injecting requiring 22:48 caution in at risk populations for blood pressure. Common side effects include 22:53 muscle pain, joint pain, pain in the limbs, nausea, headache, and dizziness. So from an integrative bone health 23:00 perspective, terrapeptides should be part of a comprehensive strategy. Adequate calcium intake, 500 to a,000 23:08 milligrams of calcium a day from food and supplements combined. and vitamin D. 23:13 Getting vitamin D levels of at least 50 to 80 are essential for the drug to work 23:20 optimally. But beyond this, bone health requires vitamin K2, which directs calcium into the bones rather than soft 23:27 tissues, magnesium as a co-actor in bone metabolism, trace minerals like boron, 23:33 copper, silica, and of course, adequate protein intake, which many of us, especially as women, don’t do 0.8 8 to 1 23:42 gram of protein per kilogram of body weight, weightbearing exercise. Of 23:47 course, these all provide mechanical signals that complement the biochemical 23:52 symbol uh signals of terrapeptide. Sequential therapy is also critical. The 23:58 bone mass gains from terraparatide can be lost if patients don’t transition to 24:05 an anti-resorbbitive agent a bisphosphinate after completing this therapy and the anabolic effects to 24:12 build bone but maintaining the new bone requires preventing excess reabsorption. 24:18 So positive things about this but there are definitely some concerns as well. So 24:23 the next one we’re going to talk about is Lu Prolrooide. It is marketed under 24:29 the multiple brand names of Lupron, Depo, Eligard, and it’s a synthetic 24:34 nonapeptide analog of naturally occurring ginonadotropen releasing 24:39 hormone G&R, also called luteinizing hormone releasing hormone, LHR. 24:46 It’s a fascinating example of how manipulating natural hormonal feedback systems can create therapeutic effects. 24:53 So, G&RH is normally secreted in a pulsatile fashion by the hypothalamus 24:59 and travels to the anterior pituitary where it binds to G&R receptors and 25:05 stimulates the release of luteinizing hormone LH and follical stimulating hormone FSH. These ginatotropins signal 25:13 the ovaries or the testes to produce sex hormones, estrogen, progesterone in 25:18 women, testosterone in men. Uh, luoprololi lupron as a GNR agonist 25:26 initially mimics the action of natural G&R causing an acute flare response with 25:33 uh increased LHFSH secretion which temporarily increases sex hormone 25:38 production. However, the continuous administration which is in the depo 25:44 formulations, the GNR receptors in the pituitary become desensitized and 25:50 downregulated. And after about 2 to four weeks of continuous exposure, LH and FSH 25:56 secretion is profoundly suppressed, leading to what’s termed as chemical 26:01 castration. Testosterone levels in men drop to castrated levels less than 50 26:08 and estrogen production is marketkedly suppressed in women. This bifphasic 26:13 response creates both therapeutic applications and management challenges in prostate cancer where tumor growth is 26:20 typically androgen dependent and the ultimate goal is testosterone suppression. However, the initial 26:27 testosterone surge during the flare phase can temporarily worsen symptoms potentially causing increased bone pain, 26:34 urinary obstruction, or even spinal cord compression in patients with metastatic 26:40 disease. This is why uh luoprolide is often started with an anti-ad androgen 26:47 like bicladamide for the first two to four weeks to block the effects of the 26:52 testosterone surge. The FDA has approved lupalide for multiple indications across 26:59 formulations. In oncology, it’s used for palletive treatment of advanced prostate cancers. In gynecology, various 27:06 formulations are approved for endometriosis, for pain management and lesion reduction and for fibroids. 27:13 Typically for pre-operative uh hematological improvement in anemic patients. In pediatrics, it’s used for 27:20 central precocious p puberty basically to halt the premature sexual development of these young people. Now, there are 27:28 adex uh adverse effect profile that reflects profound hormonal suppression. 27:34 In men treated for prostate cancer, hot flashes affect about 59% of the patients. Other common effects include 27:41 general pain, swelling, bone pain. Um long-term use of these medications leads 27:47 to metabolic changes. It increases fat mass. It decreases lean mass. It worsens 27:53 insulin sensitivity, disrupts the cholesterol uh lipid panels, increases 27:59 diabetic risk, has some concerns over cardiovascular disease. And the metaanalysis have shown increased risks 28:06 of heart infarction, myocardial inffection, sudden cardiac death, and stroke in populations receiving 28:13 long-term androgen deprivation therapy. The bone effects are particularly dramatic. Without sex hormones, bone 28:20 density decreases significantly, typically 3 to 4% per year during the 28:26 first two to three years of therapy. And this bone loss may not fully be reversible after the the therapy 28:32 discontinues. The American Society of Clinical Oncology recommends bone density monitoring and consideration of 28:39 bisphosphinates uh in men receiving long-term androgen deprivation. In women treated for 28:46 endometriosis or fibroids, the estrogen suppression creates a hypoestrogenetic state similar 28:54 to menopause. Hot flashes affect 90% of patients with other common effects 29:00 including headaches, emotional irritability, decreased sex drive, vaginal dryness, bone density loss. And 29:08 because of these bone concerns and treatment duration with endometriosis, typically limited to six months, though 29:14 some formulations allow for longer use with adback hormonal therapy to 29:20 partially mitigate these side effects. The mood and cognitive effects can be s 29:25 significant. I’ve seen it over the years. the depression, the memory impairment, difficulty focusing and 29:31 concentrating. It can be very very traumatic and the quality of life that 29:37 happens for these uh women and men can be unbearing for many of them. Um, from 29:44 an integrative perspective, patients receiving this medication need comprehensive support care. Bone health 29:51 interventions using calcium, vitamin D, vitamin K2, weightbearing exercise, 29:58 cardiovascular risk management becomes critical, including blood pressure monitoring, lipid management, diabetes 30:05 screening. For hot flashes management, some patients respond to black coohos, 30:10 sage, or vitamin E. Though evidence is mixed and individual response varies, 30:16 omega-3s may help with the mood and the inflammation, resistance training becomes specifically important to 30:22 preserve lean muscle mass in the face of hormonal suppression. 30:27 Now there’s something called calcetonin salamon which is marketed as miaelin. 30:34 It is a nasal spray. It is now discontinued. And foral is the new 30:39 synthetic polyeptide hormone of 32 amino acids identical to calcetonin of salamon 30:47 origin. It represents an interesting case study in how initial promise gives 30:52 way to safety concerns that regulate a therapy to historical footnote status. 30:58 Calcetonin is naturally occurring hormone in humans. It’s secreted by the paraphalicular sea cells in the thyroid 31:04 gland. Its primary physiological role is to lower blood calcium levels by 31:10 directly inhibiting osteoclast activity, reducing bone reabsorption, increasing 31:16 renal calcium secretion or excretion, and possibly reducing the intestinal 31:21 calcium absorption. So, salamon calcetonin is used therapeutically because it’s more potent and longer 31:27 acting than human calcetonin. The FDA initially approved calceton and salmon 31:34 for several indications post-menopausal osteoporosis in women more than five 31:39 years post-menopausal when alternative treatments are not sustainable. Padet’s 31:44 disease for bone and hypercalcemium as emergency treatments. The nasal spray formulation is particularly popular for 31:53 osteoporosis because it offered a non-injectable alternative to bisphosphinates. 31:58 However, in 2012, the European Medicine’s Agency, EMA, conducted a 32:05 comprehensive safety safety review after a poolled analysis of 21 clinical trials 32:10 involving over 10,000 patients showed a statistically significant increase in 32:15 malignancy risk in patients treated with calceton salamon compared to compared to 32:21 placebo. The overall malignancy rate was 4.1% in calcetonin treated patients 32:28 versus 2.9% in placebo patients. The types of cancer 32:34 varied with no single cancer type predominating, making it difficult to establish a clear mechanistic link. 32:41 However, the signal was concerning enough that the EMA restricted the use of calcetonin containing medicines. In 32:48 the United States, the FDA issued communications about malignancy signal and conducted its own review. While they 32:56 didn’t fully withdraw the drug, the cons consensus shifted dramatically. The nasal spray formulations miaelson was 33:03 voluntarily discontinued by the manufacturer and current clinical practice guidelines now consider 33:10 calcetonin salamon as a second line or lower option for osteoporosis. While 33:15 behind bisphosphinates, dennism mob, uh, terrapeptide, the analesic effect of 33:21 calcetonin in bone pain, particularly in acute vitibbral, uh, compression 33:26 fractions from osteoporosis or pageantss disease may still provide a role for short-term use in these selected 33:32 patients. The mechanism of this pain relief is unclear, but may involve 33:38 effects of endorphin systems and/or direct actions on pathways. The history serves as an important reminder in 33:45 peptide medicine. Initial approval and early clinical use does not guarantee 33:50 long-term safety effects. Post marketing surveillance and poolled analysis of the clinical trial data can reveal adverse 33:58 effects that weren’t apparent in initial studies. It also underscores why newer 34:04 agents with better safety profiles um have largely replaced calcetonin in 34:10 clinical practice. So this is really an important thing. Not one thing stays the same forever. We have to change as we 34:18 identify new and better products as we identify problems and concerns. I will 34:24 always tell my patients if you are uncertain of taking a new drug which we 34:30 all should be wait five years. Within five years we are going to find the 34:36 problems that they didn’t find in the clinical studies. Remember, a lot of these clinical studies are small, small 34:43 groups, short periods of time. It’s expensive to do these trials. So, if you 34:49 wait for five years, in the first two to three years, you will see the problem start to emerge. And what are you going 34:55 to look for? You’re going to look for the the news um commercials from lawyers 35:02 suing a drug. And they will tell you what the problem is. and then you can decide, is this something that I want to 35:09 use or not. Don’t jump on bandwagon and be the first one to do this, especially 35:14 if you’re sensitive. You know, give it time so you can see exactly what’s going on. So, I’m going to end our show on 35:22 this and we are going to pick up on part three of peptide therapy in our next 35:28 segment where we’re going to talk about the investigational peptides and some 35:34 exciting things that are happening with that. So, I want to thank you for joining me today on Let’s Talk Wellness 35:39 Now. It’s always a pleasure having a conversation with you guys and I hope this brings value to you with what we’re 35:45 talking about. If you have ideas for topics that you want me to discuss, 35:51 please message us, you can share your comments on Facebook, you can email us, 35:58 um you can get a hold of us however you would like to share that. I do look at the comments below in the episodes as 36:04 well. So you can place your comments there. And once again, one of the best things you can do for me is like, 36:11 subscribe, and share so that we can spread the messages of what we’re doing. 36:16 I do this at no cost. I don’t make any money out of this. I do this as an 36:21 educational purpose for everybody else. I love doing it, but it really helps us 36:28 on the algorithms if you would be just willing to like, subscribe, and share. 36:33 So, thank you for spending your time with me. I know time is important.The post Episode 257 – Peptides for Sexual Wellness & Hormonal Health: PT-141, Growth Hormones, Bone Health & More! first appeared on Let's Talk Wellness Now.

In this week's LGBTQ headlines: • The Netherlands has sworn in its first out Prime Minister, Rob Jetten • The Advocate and OUT Magazine have laid off numerous staffers amid Trump's current anti-DEI landscape • Two major medical groups are shifting their positions on gender-affirming care for young people • An estimated 16,000 people living with HIV in Florida are at risk of losing access to HIV/AIDS medications • New documentary -- "Bob Mackie: Naked Illusion" -- celebrates legendary fashion and costume designer Bob Mackie All that and more in this episode of The Randy Report.

This week on The Hamilton Review Podcast, we're pleased to welcome Dr. Jaime Deville. In this episode, Dr. Deville joins Dr. Bob for an important conversation about childhood vaccines. They explore common myths versus reality and share what parents need to know to keep their children safe and protected from preventable diseases. Don't miss this informative episode.  Jaime G. Deville, MD is a Clinical Professor of Pediatrics in the Division of Infectious Diseases at the David Geffen School of Medicine at UCLA and UCLA Mattel Children's Hospital and is the Director of the Care-4-Families Clinic at UCLA. Dr. Deville obtained his MD from Universidad Peruana Cayetano Heredia, Lima, Peru, and completed a one year Tropical Medicine fellowship at the Alexander Von Humboldt Tropical Medicine Institute in Lima, Peru, a pediatric internship at the Cayetano Heredia University Hospital in Lima, Peru, and subsequently completed his pediatric residency as well as chief residency at State University of New York Downstate Medical Center. Dr. Deville has been at UCLA since 1992 where he completed research and clinical Pediatric Infectious Disease fellowships, including a one year epidemiology fellowship at the UCLA Center for Vaccine Research. Dr. Deville is a member of the Advisory Commission in Childhood Vaccines for the Health Resources and Services Administration of the US Department of Health and Human Services, and also is a member of the National Advisory Committee of the National Hispanic Medical Association and serves as a reviewer for 13 leading medical journals. Dr. Deville's main areas of research have been in childhood vaccines, immunology and morbidity of pediatric HIV infection, neonatal and pediatric gram-positive infections. Dr. Deville has conducted studies on safety and immunogenicity of live influenza vaccine in HIV-infected children. He served as vice-chair of ACTG 351 and as a protocol team member of PACTG 1048. How to contact Dr. Bob: Dr. Bob on YouTube: https://www.youtube.com/channel/UChztMVtPCLJkiXvv7H5tpDQ Dr. Bob on Instagram: https://www.instagram.com/drroberthamilton/ Dr. Bob on Facebook: https://www.facebook.com/bob.hamilton.1656 Dr. Bob's Seven Secrets Of The Newborn website: https://7secretsofthenewborn.com/ Dr. Bob's website: https://roberthamiltonmd.com/ Pacific Ocean Pediatrics: http://www.pacificoceanpediatrics.com/

On this episode of the America's Work Force Union Podcast, we celebrate Women in Construction Week with a deep dive into the intersection of public policy, labor power, and gender equity. Our guest, Carol Kim, Business Manager of the San Diego Building and Construction Trades Council, shares the "San Diego Story"—a blueprint for how labor can reverse anti-union legislation to build a massive, stable pipeline of work. Key Topics Covered: The Long Game in San Diego: Carol details the strategic campaign to "flip" the city council and pass a ballot measure with 58% voter support to overturn the region's long-standing ban on Project Labor Agreements (PLAs). The $1B Pipeline: How a citywide PLA covering the capital improvements program is creating economic stability for more than 30,000 union workers and expanding apprenticeship slots. Women in the Trades: A candid assessment of why women's participation has climbed from 2.5% to nearly 10% in the region and the cultural shifts still required to reach equity. Childcare as Workforce Development: Why California's ERICA program (Equal Representation in Construction Apprenticeships) is a game-changer for retaining women who are primary caregivers. From Teacher to Labor Leader: Carol reflects on how her background in education and HIV prevention shaped her approach to organizing and why she views labor as the most effective tool for fighting structural poverty. What You'll Learn: Why the nature of construction makes citywide PLAs essential for worker stability, and how intentional mentorship is transforming the face of the San Diego job site. For more information on the San Diego Building and Construction Trades Council, visit sdbuildingtrades.com.

As Sheletta plans to put on her ropers and rope her a cowboy at the Houston Livestock Show & Rodeo, she wants to make sure both she and her future Boo are safe before they get too serious. She asked her friends form Harris County to join her to talk about their HIV prevention programs and how residents can take advantage of the services they offer.

Wie geht man als mündiger, lebenslustiger Mensch mit Geschlechtskrankheiten um? Wie sollte man sich verhalten, was sollte man wissen, wie oft sich testen lassen? Das habe ich Mirjiam Hall gefragt. Sie ist Gynäkologin und Vorsitzende der Aids Hilfe Wien. Wie man Risiken reduziert, ohne sich verrückt zu machen.

Hello Poz Vibers!Veda and Robbie decided to hand the mic to tribe member Luis Noguera Benitez to host the pozcast this week. Luis is an Irish Venezuelan actor, journalist and activist whose focus is fighting HIV stigma. His guests this week are Maho and Avatar both from Venezuela. Avatar Guille is originally from Caracas and recently celebrated 10 years living in Ireland. For almost 4 years, Avatar lived in Direct Provision here but has set up a big life here since. Not only has he studied at IADT in Dun Loghaire but he has also performed all over the country including at The Gate Theatre, The Everyman in Cork, Electric Picnic andMother Block Party. Maho is a queer journalist and founder of Moh flowers art and design in Dublin. Maho is also a mother and says they care deeply about social and political activism, freedom and democracy.Welcome to the tribe!Love,Veda and Robbie.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Poz Vibe Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ is a⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Veda⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Lady and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Robbie Lawlor⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ production. Big thanks to ⁠our sponsors ⁠⁠⁠⁠⁠⁠Dublin Pride ⁠⁠⁠⁠⁠⁠who make this series possible. We'd also like to thank The Boiler House, Man 2 Man, Gay Health Network and The George for all their help and support.Episodes are produced by Veda and Robbie with production assistance and editing by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Esther O'Moore Donohoe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Video editing, artwork, social media assets and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ merch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ all created by Lavender The Queen.⁠⁠ ⁠⁠⁠⁠

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW's Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

In this week's LGBTQ headlines: • The Netherlands has sworn in its first out Prime Minister, Rob Jetten • The Advocate and OUT Magazine have laid off numerous staffers amid Trump's current anti-DEI landscape • Two major medical groups are shifting their positions on gender-affirming care for young people • An estimated 16,000 people living with HIV in Florida are at risk of losing access to HIV/AIDS medications • New documentary -- "Bob Mackie: Naked Illusion" -- celebrates legendary fashion and costume designer Bob Mackie All that and more in this episode of The Randy Report.

This episode explores how sustained scientific ambition, backed by flexible philanthropy, has helped transform HIV from a fatal diagnosis into a manageable condition and why the search for a cure remains both urgent and achievable. At the centre of the conversation is the work of amfAR and its distinctive role in advancing research that changes lives far beyond a single disease area. Founded in the mid-1980s, at a time when HIV and AIDS were poorly understood and highly stigmatised, the organisation emerged from the determination of clinicians, researchers and advocates who refused to wait for slow-moving systems to respond. From the outset, the mission was clear: fund innovative research quickly, support bold ideas early, and accelerate scientific discovery where it was needed most. Since its first grants in 1985, the organisation has invested nearly one billion dollars in research and supported more than 3,900 researchers across the world. Rather than simply awarding grants, its approach has been to invest in people and ideas, often at the earliest and riskiest stages. Many of those early investments have gone on to underpin treatments now used globally, including antiretroviral therapies that allow people living with HIV to lead long, healthy lives. The episode places this progress in today's global context. More than 40 million people worldwide are living with HIV, with around 1.3 million new infections each year. While treatment has transformed outcomes in many countries, access remains deeply unequal. Women and girls account for over half of those living with HIV globally, and people in low-income and marginalised communities, particularly in sub-Saharan Africa, continue to face life-threatening barriers to care. Against this backdrop, the case for a cure remains compelling. Lifelong treatment depends on stable health systems, consistent access and freedom from stigma, conditions that are far from guaranteed. A cure would remove these structural vulnerabilities. Importantly, the science now points to possibility. Around ten individuals have been effectively cured of HIV, providing researchers with vital clues and a credible roadmap. Current cure-focused research is tackling some of the most complex questions in virology. This includes understanding latent viral reservoirs, where HIV hides in the body, and finding ways to reactivate and eliminate the virus. Researchers are also studying elite controllers, people whose immune systems suppress HIV without medication, to uncover mechanisms that could inform new treatments. Alongside this, insights from cancer, ageing, autoimmune disease and other viral infections are increasingly shaping HIV research, highlighting the interconnected nature of scientific discovery. A key theme running through the conversation is what defines a viable cure. It must be scalable, affordable and easy to administer, not a solution that only works in specialist settings. This emphasis on real-world applicability shapes funding decisions and research priorities. The funding model itself is central to this work. Research is supported entirely through private philanthropy, from individual donors and family foundations to global fundraising events. Independence allows decisions to be driven by science rather than politics, while short funding timelines enable researchers to move quickly. Rigorous peer review ensures standards remain as high as those of major public institutions, without the inertia that can stifle innovation. Beyond HIV, the episode highlights how this model has influenced advances in other fields. Research originally funded to understand HIV has contributed to breakthroughs in cancer immunotherapy and vaccine development, including technologies later used in mRNA vaccines. Today, the organisation is expanding its focus to areas such as cancer, Alzheimer's disease, immunotherapy and artificial intelligence, particularly where these intersect with the needs of an ageing HIV-positive population. Woven throughout the discussion is the human impact of research. Funding science does more than produce data and treatments; it provides hope. Knowing that researchers are actively working towards a cure can fundamentally change how people live with a diagnosis. Investment in early-stage research becomes an investment in dignity, longevity and possibility. The episode closes with a clear message. Scientific discovery is not confined to governments or large institutions. Individuals and philanthropists can play a decisive role in advancing research that affects every household. Supporting bold ideas early is one of the most powerful ways to accelerate global health progress and, ultimately, to help make AIDS history. Visit our Knowledge Hub at Lidji.org for information on 350+ case studies and interviews with remarkable leaders in philanthropy, sustainability and social entrepreneurship. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and regulatory evolutions shaping the landscape of medicine.One of the most significant recent developments involves Boehringer Ingelheim's drug Hernexeos, which has seen a rapid expansion in its use as a first-line treatment for non-small cell lung cancer (NSCLC). This expansion was made possible through the FDA's Commissioner's National Priority Voucher, an initiative designed to fast-track the approval of treatments addressing critical needs. This rapid progression highlights a commitment to accelerating access to crucial oncological treatments, emphasizing the role of accelerated regulatory pathways in swiftly delivering innovative therapies to patients who need them the most.In oncology, a combination therapy involving Padcev and Keytruda is showing promising results in improving overall survival rates for patients with muscle-invasive bladder cancer who are eligible for cisplatin. However, the continuously evolving landscape of treatment options for this cancer type means that further evaluation is necessary. This scenario highlights the ever-changing nature of oncology strategies and the ongoing need for clinical validation to determine the most effective treatment regimens.Switching gears to immunology, UCB's Bimzelx has reached a significant sales milestone, reflecting its growing influence in treating multiple indications. This success points to an expanding market for immunology therapeutics, as the industry remains focused on developing blockbuster treatments that can serve various conditions effectively.On the regulatory front, Moderna's combination influenza/COVID-19 vaccine has received a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use. This green light exemplifies the EU's dedication to thorough scientific evaluations. It contrasts with the FDA, which has exhibited hesitancy in this area, highlighting how varying regulatory approaches can affect drug availability in different regions.The field of HIV treatment is also seeing progress with GSK's ViiV division confirming the efficacy of its long-acting Cabenuva regimen for adolescents over a 96-week period. This long-acting regimen provides an alternative to daily oral therapies, potentially improving adherence and outcomes among younger populations—a crucial factor in managing chronic conditions effectively.Meanwhile, legal developments are stirring as the debate over "skinny labeling" for generic drugs reaches a pivotal point. The U.S. Supreme Court is being urged to overturn a ruling that endangers this pathway, highlighting the fine balance between fostering generic drug competition and protecting pharmaceutical innovation. In related legislative discussions, a Senate hearing focused on the FDA's rare disease review process has brought to light concerns about bureaucratic obstacles that may slow innovation. There is a call from stakeholders for more streamlined processes to ensure timely access to treatments for rare diseases—a sentiment echoed by many in the industry.The burgeoning field of CAR-T cell therapies continues to make waves, especially against solid tumors. Recent preclinical studies have shown potential efficacy in eradicating solid tumors in mice models. Despite these promising findings, significant regulatory challenges remain, and streamlining approval processes could accelerate their clinical application.In other significant news within the industry, Novartis has completed its acquisition of Avidity Biosciences for $12 billion, leading to the creation of Atrium Therapeutics. With a capitalization of $270 million, Atrium emerges with two promising preclinical candidates targeting cardiovascular conditions, signaling potential advSupport the show

A new center for the study of chronic infectious diseases aims to develop treatments for illnesses like Valley fever, tuberculosis, HIV, and Long COVID that disproportionately affect South Texas communities. Led by Dr. Barbara Taylor, the center seeks to attract top researchers and serve as a hub for clinical trials and community-focused care.

In episode 70 of Going anti-Viral, Peter Staley joins host Dr Michael Saag after giving the Martin Delaney presentation at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) entitled ''Annus Horribilis" and The War on Science: Thoughts on Resisting and Rebuilding. Mr Staley shares his inspiring story as a pioneering HIV and LGBTQ+ rights activist, recounting his journey from the early days of the AIDS crisis to groundbreaking activism leading to a seat at the table with clinicians and researchers in bringing life-saving treatments to people with HIV and AIDS. Dr Saag and Mr Staley also reflect on the recent era of anti-science activism during the COVID-19 pandemic and share their advice for young researchers who may be the generation of scientists that bring about a cure for HIV.0:00 – Introduction 2:30 – The early days of AIDS awareness6:23 – Peter's reflections on his positive HIV test result10:46 – Transitioning from Wall Street to activism12:11 – The formation ACT UP and impact of Larry Kramer15:22 – Channeling anger into activism17:47 – Targeting the FDA and the fight for drug access20:26 – The role of the NIH and Tony Fauci 24:10 – The Parallel Track: access to experimental drugs25:40 – The role of the Treatment Action Group (TAG) and the AIDS Clinical Trials Group (ACTG)26:32 – The breakthrough: viral load and undetectable levels31:18 – Reflections on COVID-19: activism in a new era33:45 – Prep4All: advocating for access to PrEP38:38 – Advice for young clinicians and closing remarksResources:Watch Peter Staley's presentation at CROI 2026 ''Annus Horribilis" and The War on Science: Thoughts on Resisting and Rebuilding YouTube:  https://youtu.be/p5kqUujWPCs PrEP4All: https://prep4all.org/ CROI 2026: https://www.croiconference.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Epstein scandal highlights how women and girls are silenced: UN Human Rights chief Fears grow for Afghan civilians after reported Pakistan air strikesDenmark eradicates mother-to-child transmission of syphilis, HIV

From a volunteer-run initiative in the 1980s to a regional continuum of care in 2026: On this episode of Discover Lafayette, we sit down with Claude Martin, CEO of AcadianaCares, to talk about what it looks like when a community builds an institution out of necessity, and then keeps rebuilding it for four decades. AcadianaCares began (originally as “Lafayette CARES”) in 1985, during the earliest, scariest years of the HIV/AIDS epidemic, when fear and stigma shut down many traditional systems of response. “CARES” stood for “Concern for AIDS Relief, Education and Support.” Claude remembers those first years in deeply personal terms: “I got involved with this work, HIV work in the early 80s when our community started to get sick.” He describes a time when an HIV diagnosis in Louisiana carried a terrifying prognosis saying, “the life expectancy was about nine months.” The uncertainty felt like a public-health free fall. When we talk about how frightening those early days were, Claude agrees without hesitation: “Very similar to the fear and confusion many of us felt during COVID. Who's going to get it? and what do we do now?” Claude explains that what became AcadianaCares wasn't a government-created program; it was community members stepping in when institutions froze. “It was a groundswell of people saying, I have to do something. We have to do something.” For years, it ran on sheer willpower. “We were volunteers, running it out of our houses. We all had full-time jobs.” Claude's own job then was far from nonprofit administration as he worked as a landscaper. And while the organization was being built, people were dying. Claude doesn't sanitize that reality. “Sometimes they came to a couple of meetings and then they were in the hospital; within a month they were dead. They were gone.” In those first ten years, he says, “We really were concentrating on helping people to die. We were there.” He describes practical, human-scale solutions built by ordinary people: a hotline routed into volunteers' homes, partnerships for training, and a “Buddy program” where volunteers went into homes to help with the basic tasks of living: cleaning an apartment, getting to appointments, answering desperate late-night questions from people who felt helpless. From there, the story becomes one of evolution, not away from HIV care, but outward from it. Claude explains that in the early 2000s, AcadianaCares started asking a different question: if HIV is the core mission, what are the destabilizing forces that make people more vulnerable in the first place? In his words: “Mental illness, homelessness, substance abuse are three of the big areas that really do destabilize people's lives.” That mindset shaped the modern AcadianaCares model: a system designed so that someone can enter through one doorway to have access to housing, clinic, and recovery, and then be “wrapped around” with the rest. The medical reality has changed — and AcadianaCares is trying to reach the whole community Claude also walks us through the medical transformation he's witnessed across the decades. “The pharmaceutical industry has developed all of these medications so that now life expectancy is open ended.” He explains how viral load suppression changes both individual health and transmission risk. When treatment is working, people are no longer infectious. He points to PrEP as a powerful prevention tool: “PrEP is about 99%” effective in preventing acquisition. The goal he lays out is ambitious and clear: get people living with HIV to an undetectable viral load and get people at risk onto PrEP. “Conceivably, we will get to the point where we have no new infections.” Claude shares the regional scope, then and now. He remembers: “There were 11 people in Lafayette Parish that were living with HIV in 85.” Today, he says, “we have 2000 people that are living with HIV in our region,” with about 75 to 100 new infections every year in the seven parish area. Expansion on the northside: “whole-person care in one place” We also discuss AcadianaCares’ expansion of clinical services on Lafayette's northside. Claude explains that the clinic model exists because they were seeing people newly diagnosed with HIV struggling to get into care quickly. “We were having a really hard time getting people into care once we found out that they were positive.” So they built a system where patients could be seen and started on care faster. AcadianaCares purchased and renovated Pride Plaza at Willow and Pierce, turning it into a primary care clinic open to the public. The clinic has a staff of 32 in its 8,900 square-foot space offers a full spectrum of primary care and mental health services available to both insured and non-insured patients. Dr. Clinton Young is at the clinic specializing in sleep medicine and complex sleep-related disorders. Moving clinic services into Pride Plaza also created room on the main campus for expanded substance-abuse programming. AcadianaCares developed Seasons of Serenity (SOS), a network of residential, outpatient, and sober living recovery programs. Clients in SOS transition from dependency to self-sufficiency through structured phases in a safe and caring environment that is free from discrimination. AcadianaCares celebrating its 40th anniversary and opening of the new Primary Care Mental Care and Pharmacy in February 2026. In our conversation, Claude describes the wraparound approach inside the clinic, not just medical appointments, but navigation help: “Our clinic patients have access to navigators who help them apply for insurance… everything from food stamps to finding other agencies.” He contrasts that with many healthcare settings: “A lot of people go to a provider, but they don't have the social services support or the wraparound support.” The MLK campus: housing + recovery, built over time One of the most substantive parts of our conversation is Claude's description of the Acadiana CARES campus on Martin Luther King Jr. Drive in North Lafayette: housing and recovery programs built through long-term planning, grants, and renovation. The site is located at 809 Martin Luther King Jr. Dr. in North Lafayette. “We have housing there and about 80 people live on the property.” The site originally housed the Lafayette Guest House, formerly a 206-bed nursing facility with an inpatient psychiatric hospital, Oceans Behavior Healthcare, was donated to AcadianaCares by its owners, Jerrine Harrell, Donna McPherson, and John Wright. The owners made the decision to donate the property, valued at approximately $3.5 million, in order to do something good for the community and also be able to claim a charitable donation on taxes. Catholic Charities of Acadiana’s Kim Boudreaux James is the niece of Wright and she helped identify AcadianaCares as the best fit for the donation. (For a comprehensive story of the background of this donation and how it transformed AcadianaCares, see https://theind.com/articles/842/. ) He walks through the arc of development: a major donated property, then years of grants and fundraising to renovate and convert spaces into apartments, and then major investments in addiction treatment. He explains that their Seasons of recovery program now offers “the whole continuum of care,” describing transitions from detox, to a 28-day program, to a 90-day residential program, then outpatient services, and supportive apartment options designed to help people stabilize, work, save money, and re-enter independent life. Claude shares one of the concrete, practical details people often want to know: the outpatient apartment option is “$416” and includes “three meals a day, seven days a week.” He explains the program design goal plainly: “in six months, you ought to be able to save enough money to be independent.” AcadianaCares’ Seasons of Serenity receive referrals statewide: “We get referrals from all over the state,” and adds, “we get probably 7 to 10 referrals a day.” The reality is capacity: “All of our programs are usually at capacity.” Growth that still comes back to one measuring stick Claude has led AcadianaCares through extraordinary growth. He recalls the first state grant: “$34,000.” Today, he says, “our board just approved a $34 million budget.” He notes scale: “We have about 100 employees here, and we help an average of 4000 people a year.” In 2025, 2,495 unique patients received care through its wellness clinic. Its reach is across 25 zip codes in Lafayette, Acadiana, Evangeline, Iberia, St. Landry, St. Martin, and Vermilion parishes. Claude Martin joined AcadianaCares in 1998, after serving as an original volunteer in its early days. “I felt called to do the work. In the early 90s, I went back to school and got a graduate degree in rehabilitation therapy. All my work was focused on getting people living with HIV and having that treated as the same thing that’s a head injury or a substance abuse issue or a mental health issue that would debilitate someone. That degree is designed to help as a life changing experience. to move them through that process and get them back into this life.” But one of the most telling moments in our conversation is his personal standard for quality and dignity. The question he asks himself when planning services and facilities: “Would I let my mother or my sister receive services here?” He connects that directly to the mission: bringing high-quality care to people who often don't have choices, and who may have been neglected for years. Advice for families facing addiction Near the end, Claude offers direct advice to families navigating substance use disorder. His first recommendation is simple and specific: “Join an Al-Anon group.” He explains why: “It's realizing that it's a family disease,” and stresses that the work includes shifting attention toward self-care: “take the focus off of the alcoholic and look at taking care of yourself.” And yes — he shows standard poodles Claude also shares a surprising personal and fun detail that gives listeners as we wound down the interview: “I show dogs. I breed standard poodles.” He competes nationally, and he says, “We won at the nationals last year; Tallulah won the best standard poodle.” It's a reminder that even people carrying enormous community responsibility have a life and identity beyond the mission, and sometimes a very competitive hobby. Claude Martin’s young standard poodle, Talulah, being shown by handler, Kay Peiser, at the Poodle Club of America’s 2025 nationals competition. She won “Best Standard Poodle.” Connect with AcadianaCares Main Office: (337) 233-2437AcadianaCares : (337) 704-0787Pharmacy: (337) 216-1013Locations: 809 Martin Luther King Jr. Drive, Lafayette, and 850 North Pierce Street (Pride Plaza Clinic / Pharmacy area), Lafayette For more information, visit https://www.acadianacares.org/

Matthew Bannister onMartyn Butler who was a central figure in the UK's early response to HIV and AIDS. He was a co-founder of the Terrence Higgins Trust and gave his own home phone number as a helpline.Allan Massie, the Scottish author and critic whose hero was Sir Walter Scott. Sir Ian Rankin pays tribute. Professor Nicola Fear, the epidemiologist who studied the effects on military personnel of serving in the Iraq War and Afghanistan.Willie Colón, the American trombonist who was inspired by his Puerto Rican heritage to create salsa music.Interviewee: Tony Whitehead Interviewee: Sir Ian Rankin Interviewee: Professor Sir Simon Wessely Interviewee: Garth CartwrightProducer: Gareth Nelson-Davies Assistant Producer: Ribika Moktan Editor: Glyn TansleyArchive used: Martyn Butler seminar recording, Terrence Higgins Trust, THT YouTube channel, uploaded 26/06/2022; Terrence Higgins Trust actuality recording, Week In Week Out, BBC Wales, 29/10/1985; News report, BBC News, 08/01/1987; Advert: Iceberg, Department of Health and Social Security, Dir Nicolas Roeg, Voiceover: John Hurt, 1987; Allan Massie, The Book Programme: First Novels, BBC Two, 11/02/1978; Allan Massie interview, France Politics, Writers Revealed, BBC Radio 4, 06/07/1992; Allan Massie interview, General Election Report, BBC News, 10/04/1997; Nicola Fear, The Fear Factor: life as a military epidemiologist, King's College London, uploaded to YouTube on 23/04/2018; Iraq War news report, BBC News, 31/03/2009; Afghanistan News Report, BBC News, 27/10/2014; Willie Colon interview, Latin Music USA, BBC Four, 05/02/2010;

David chats to Gary Pargeter and Sally Clarke, the new Wellbeing Worker and Volunteer Coordinator for Lunch Positive.https://lunchpositive.org/Sue and Josh discuss World, National and local HIV news.

We hear from a Mexican city in Sinaloa state where one of the big drug cartels is locked in its own civil war. Our correspondent Quentin Sommerville visited the state capital, Culiacán, where he witnessed scenes of brutal violence that have brought pain and terror to residents. Also: Cuba says its coastguard has killed four people on board a US-registered speedboat, in an exchange of fire off the Cuban coast. It said those on the boat were Cubans, living in the US, with a history of violent activity - and "terrorist" intentions. The American Secretary of State, Marco Rubio, called the shootout "highly unusual" and said the US would conduct its own investigation into the incident and not rely on the Cuban version of events. A British clinical trial on more than 500 people across 15 countries found that a new tablet to treat HIV - which combines two current treatments - is highly effective at keeping the virus suppressed. A BBC Eye investigation has revealed that Nepal's top police officer gave the order allowing the use of live fire during last year's deadly crackdown on Gen Z protests - one of the worst in the country's history. And the robot that conducted Denmark's National Symphony Orchestra. We have the verdict on its performance. The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk

We hear from a Mexican city in Sinaloa state where one of the big drug cartels is locked in its own civil war. Our correspondent Quentin Sommerville visited the state capital, Culiacán, where he witnessed scenes of brutal violence that have brought pain and terror to residents. Also: Cuba says its coastguard has killed four people on board a US-registered speedboat, in an exchange of fire off the Cuban coast. It said those on the boat were Cubans, living in the US, with a history of violent activity - and "terrorist" intentions. The American Secretary of State, Marco Rubio, called the shootout "highly unusual" and said the US would conduct its own investigation into the incident and not rely on the Cuban version of events. A British clinical trial on more than 500 people across 15 countries found that a new tablet to treat HIV - which combines two current treatments - is highly effective at keeping the virus suppressed. A BBC Eye investigation has revealed that Nepal's top police officer gave the order allowing the use of live fire during last year's deadly crackdown on Gen Z protests - one of the worst in the country's history. And the robot that conducted Denmark's National Symphony Orchestra. We have the verdict on its performance. The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk

“Being gay is like turning on the sink and water just comes out.” According to a a popular influencer is that Sex is easily obtainable...is it? We discuss... Or is that something only some gay men experience? And if it is easy… why does love feel so much harder? The hosts discuss when they felt like sex was more accessible in gay spaces... Is sex built into our gay community for some of us but then is affection and love that much harder to find without any examples or tools? Do body image, age, race and proximity all affect how gay men obtain sex on the apps? Is sex easier to get in certain spaces... Hot Topic: Disability activist says BBC cut Homophobic slur but kept a racist one in... Hot Topic: Can PrEP among gay Black men be improved when the stats show this community has the highest HIV new infections? Hot Topic: Married influencers Toby and Mikey Perryman-Payne recount be drugged at a gay bar in LA back in 2024 and how it affected them... Hot Topic: Gay Days in Orlando is back! Hot Topic: Gay True Crime Must See TV - "Murder in Glitterball City". Advice: Is it important to date multiple people to decide if the one you are currently dating is the one? Advice: Glory Hole etiquette - is there any etiquette?? Thirst Trap: Which of these 13 models took the best pic of the week? Visit: Steve V's new app - Studio.com/stevev for the website version and visit the app version: Studio.com/stevev/connect Follow Stevie on IG: @iam_stevev Follow Kodi on IG: @mistahmaurice Rate and Review us! Wanna drop a weekly or one time tip to TAGSPODCAST - Show your love for the show and support TAGS! Visit our website: tagspodcast.com Needs some advice for a sex or relationship conundrum? Ask TAGS! DM US ON IG or https://www.talkaboutgaysex.com/contact Follow Of a Certain Age on IG: @ofacertainagepod Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It started with a simple moment. Lunch. A new romantic relationship. Feeling good about the future. Then a thought slipped in: what if I have an STD and just don't know it? That's how OCD entered Will Schultz's life. What began as one intrusive question quickly spiraled into fears of HIV, contaminated needles, rabies, and eventually a deep distrust of his own memory and senses.On this episode of the Get to Know OCD podcast, Will shares how that single “what if” thought grew into years of fear, and what finally changed. Even after learning it was OCD and knowing the right treatment, he still struggled to face it. Recovery didn't begin with more reassurance. It began when he made a decision: staying safe was no longer the priority — confronting OCD was.At NOCD, we specialize in exposure and response prevention therapy (ERP), the most effective treatment for OCD—a treatment that can help you live a fulfilling life. If you're ready to take your first step, book a free 15-minute call with us at https://learn.nocd.com/YTFollow us on social media:https://www.instagram.com/treatmyocd/https://twitter.com/treatmyocdhttps://www.tiktok.com/@treatmyocd Hosted on Acast. See acast.com/privacy for more information.

Africa Melane chats to SANAC’s Nelson Dlamini about treasury allocating R26bn to provinces to sustain HIV/AIDS treatment. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

  We welcome Oni Blackstock, M.D., M.H.S., to our miniseries of interviews with people who are leading some of the big conversations we're having as a health care community during a time of great change, and great strain, in HIV care provision within the U.S. Dr. Blackstock shares what has motivated her multiple evolutions along the arc of her career from HIV/PCP physician to NYC DOH assistant commissioner to health equity consultant, and the lessons she has learned along the way.   Read the transcript on TheBodyPro (every click helps!): https://www.thebodypro.com/podcast/hiv/future-hiv-care-oni-blackstock-feb-2026    The host and executive producer of this podcast is Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; and our audio editor is Kim Buikema. Special thanks this month to contributing science editor Roger Pebody for his help with background research and interview prep.

Jase and Al welcome John and Paula Godwin to reflect on the kind of community that shows up in the hardest moments from medical crises to marital collapse and everything in between. They revisit seasons of fear, loss, and uncertainty, including Paula's HIV needle-stick scare and the painful surgeries that tested Jase and Missy's resolve. The conversation builds to the powerful “even if” faith of Daniel 3 — trusting God not only when He delivers what we ask for, but even if He doesn't. In this episode: 1 John 2, verses 3–6; 1 John 3, verses 16–24; 1 John 4, verse 10; Daniel 3, verses 16–18; John 17 “Unashamed” Episode 1277 is sponsored by: https://fastgrowingtrees.com — Get 20% your first purchase when using the code UNASHAMED at checkout. https://bravebooks.com/unashamed — Get 20% off with code UNASHAMED https://myphdweightloss.com — Find out how Al lost 80+ pounds. Schedule your one-on-one consultation today by visiting the website or calling 864-644-1900 and mention "AL" https://ruffgreens.com — Get a FREE Jumpstart Trial Bag for your dog today when you use promo code Unashamed! http://unashamedforhillsdale.com/ — Sign up now for free, and join the Unashamed hosts every Friday for Unashamed Academy Powered by Hillsdale College Check out At Home with Phil Robertson, nearly 800 episodes of Phil's unfiltered wisdom, humor, and biblical truth, available for free for the first time! Get it on Apple, Spotify, Amazon, and anywhere you listen to podcasts! https://podcasts.apple.com/us/podcast/at-home-with-phil-robertson/id1835224621 Listen to Not Yet Now with Zach Dasher on Apple, Spotify, iHeart, or anywhere you get podcasts. Chapters: 00:00 Welcome John & Paula Godwin 04:20 Mia's Surgery & Showing Up in Crisis 09:40 Paula's First Impression  16:15 Marriage Collapse & Carrying Grace 24:30 Becoming Grandparents After Loss 30:50 Why Real Community Requires Commitment 37:40 Believe in Jesus & Love One Another 44:45 The “Even If” Faith of Daniel 3 52:30 Godwin's Fishing Guide Life -- Learn more about your ad choices. Visit megaphone.fm/adchoices

The United States is ending its health programmes in Zimbabwe, including HIV treatment for one point two million people. The US embassy said Harare had pulled out of negotiations over a new health aid agreement which would have provided 367 million dollars over five years. The US has been renegotiating aid to Africa following the abolition of USAID by President Trump.   Also on the programme: The influential economist, Larry Summers, resigns from Harvard over the Epstein files and the Microsoft co-founder, Bill Gates, apologises to staff about his links with the convicted sex offender; and we'll hear why Emperor penguins are facing the threat of extinction.   (Photo shows a health official opening a rapid HIV test during the launch of Lenacapavir, a long‑acting HIV prevention injection outside Harare, Zimbabwe on 19 February 2026.Credit: Philimon Bulawayo/Reuters)

This week, we explore a new standard of care for high-risk HER2-positive early breast cancer, long-acting therapy for people with HIV facing adherence challenges, a first-in-class trial of a p53 reactivator, and tecovirimat for mpox. We review group B streptococcal disease and a revealing case of prosthetic joint infection. Perspectives examine the role of folate therapy, Medicare drug-price negotiation, AI in medical education, and incidental findings.

Robin Beach is an HIV specialist who began to turn a critical eye to the usefulness of body mass index (BMI) when it came to understanding the overall health of a patient. On the latest episode of NP Pulse: The Voice of the Nurse Practitioner®, she speaks with Sophia Thomas about using waist circumference as a way to measure the health of specific patient populations instead of BMI, and offers practical strategies for bringing this new tool into routine practice. 

Drugs and gangs have created an explosion in HIV cases in Fiji.This week on Battle Lines: Global Health Security, Arthur Scott-Geddes is joined by Sarah Newey, The Telegraph's correspondent in Bangkok who recently travelled to Fiji, and Dr Jason Mitchell, the head of the country's HIV task force.On the archipelago known as the gateway to the Pacific, Chinese triads, Mexican cartels, and Australian biker gangs are all involved in a booming methamphetamine trade.The result is that an island paradise is now home to the fastest-growing HIV epidemic on earth.Read Sarah's dispatch from Fiji:The island paradise with the world's fastest growing HIV epidemichttps://www.telegraph.co.uk/global-health/science-and-disease/fiji-island-paradise-with-the-worlds-fastest-growing-HIV-epidemic/Producer: Sophie O'SullivanExecutive Producer: Louisa WellsStudio Operator: Meghan Searle► Sign up to our most popular newsletter, From the Editor. Look forward to receiving free-thinking comment and the day's biggest stories, every morning. telegraph.co.uk/fromtheeditorContact us with feedback or ideas:battlelines@telegraph.co.uk@venetiarainey@ascottgeddes Hosted on Acast. See acast.com/privacy for more information.

In episode 69 of Going anti-Viral, Dr Kevin Saunders joins host Dr Michael Saag to discuss a plenary presentation he gave at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) entitled Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Sciences' Most Difficult Vaccines. Dr Saunders is the associate director for the Duke Human Vaccine Institute and the Norman L. Letvin Professor in Immunology and Infectious Diseases Research. Dr Saunders leads a translational research program that designs and evaluates HIV-1 vaccines. Dr Saunders shares his journey from studying T-cell immunity to pioneering HIV vaccine research. He discusses the challenges of developing an HIV vaccine, the promise of broad neutralizing antibodies, and the innovative use of mRNA technology. Dr Saunders also shares his outlook and optimism for the next 5 years of HIV vaccine development including the use machine learning and artificial intelligence technologies to accelerate the development timeline.0:00 – Introduction 1:36 – Path to HIV research and vaccine development3:50 – Understanding T-cell immunity and HIV6:53 – Transition to passive immunity and broad neutralizing antibodies11:35 – Challenges in developing an HIV vaccine15:25 – Current state of HIV vaccine research17:38 – The role of immunogens in vaccine development20:30 – Combining B-cell and T-cell responses24:59 – Prospect for a HIV vaccine within the next 5 yearsResources:CROI 2026: https://www.croiconference.org/Duke Human Vaccine Institute - https://dhvi.duke.edu/__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Particulate matter is, Michael Greenstone argues, the greatest public health threat on the planet. Worse than HIV, cigarettes, and alcohol. The average person  loses about two years of life expectancy to it. In India, the figure is three and a half years. The solution to this problem has been tested, and it works, at least in high-income countries.Greenstone and his co-authors ran a randomised controlled trial in Surat, Gujarat: from 300 industrial plants, mostly making textiles, all burning coal, half were randomly assigned to a market where pollution permits could be bought and sold. The results: in the market, pollution fell 25%, compliance was near-perfect, and abatement costs dropped 12%. The cost-benefit ratio is as high as 200 to one. Many plants in the control group asked to be moved into the market.The research behind this episode:Greenstone, Michael, Rohini Pande, Nicholas Ryan, and Anant Sudarshan. 2025. "Can Pollution Markets Work in Developing Countries? Experimental Evidence from India." Quarterly Journal of Economics 140 (2): 1003–1060. An ungated version is available as BFI Working Paper 2025-53.To cite this episode:Phillips, Tim. 2025. "Can Pollution Markets Work in Developing Countries?" VoxDev Talk (podcast).  Assign this as extra listening: the citation above is formatted and ready for a reading list or VLE.About Michael GreenstoneMichael Greenstone is the Milton Friedman Distinguished Service Professor in Economics at the University of Chicago, where he is the founding Director of the Energy Policy Institute at Chicago (EPIC) and the Institute for Climate and Sustainable Growth. His research focuses on the costs and benefits of environmental quality, including the Air Quality Life Index, which tracks the toll of particulate pollution country by country. He previously served as Chief Economist for the President's Council of Economic Advisers under President Obama. Research cited in this episodeAir Quality Life Index (AQLI), Energy Policy Institute at Chicago. The source of the life-expectancy statistics used in this episode: particulate pollution costs the average person on Earth roughly two years of life expectancy, with India averaging three and a half years. The index tracks this burden country by country, city by city.The US sulphur dioxide cap-and-trade programme, established under the 1990 Clean Air Act Amendments, was the canonical precedent Greenstone cited: a market that dramatically reduced acid rain in the eastern United States at costs far below pre-programme projections. He noted that the UK and EU have since built comparable CO2 markets. All have worked well. The question this experiment addressed was whether the same logic held in the developing world, where almost all the pollution now is.Emissions Market Accelerator. An independent scale-up organisation founded by Greenstone and colleagues to replicate the Gujarat model beyond the original research setting. Current pipeline: a statewide sulphur dioxide market for Maharashtra (including large power plants, not just textiles), and advanced conversations in Pakistan and Brazil. Within Gujarat, a water pollution market is also in development.More VoxDev Talks on this topicRegulating pollution in low- and middle-income countries Rohini Pande and Nicholas Ryan, two co-authors of the paper discussed in this episode, on the political economy of pollution regulation in developing countries: why enforcement is hard, and what makes it work.Air pollution and infant mortality Jennifer Burney on the health costs of particulate air pollution for young children, and what the evidence from Saharan dust patterns across Sub-Saharan Africa reveals about exposure and mortality.The Social Cost of Carbon Michael Greenstone's earlier VoxDev Talk, on how assigning a monetary value to carbon emissions can drive better policy decisions and make the case for action that regulation alone struggles to make.Related reading on VoxDevReducing air pollution: Evidence from payments to reduce crop burning in India How cash payments to farmers in northern India changed behaviour and cut the seasonal haze from crop fires that pushes Delhi's air quality to its worst each winter.Paying to pollute: How carbon offsets actually raised emissions in China A cautionary study on market-based pollution controls: when incentives point the wrong way, a market can make things worse rather than better.The effect of pollution on worker productivity: Evidence from call-centre workers in China Air pollution reduces cognitive performance and output, adding an economic productivity argument to the health case for cleaning the air.

Against a backdrop of violent anti-semitic and anti-indigenous attacks and the relaxation of police restraints in response to them, Sydney Gay and Lesbian Mardi Gras organizers are faced with twin controversies: the withdrawal of the Jewish group Dayenu from the event and demands for the expulsion of the New South Wales Police contingent. Veteran activist Ken Davis explains the situation (Barry McKay reports). New Yorkers defy the Trump administration and replace the rainbow flag the government “disappeared” from the Stonewall National Monument (Paul DeRienzo of WBAI reports). A Black History Month Rainbow Rewind honors Langston Hughes (produced by Sheri Lunn and Brian DeShazor). And in NewWrap: the European Parliament approves a resolution specifically calling for “the full recognition of trans women as women,” HIV-positive enlistees are once again banned from serving in the U.S. military, intersex children are now protected from undergoing unnecessary medical procedures without their informed consent in the Australian state of Victoria, Kansans can now sue if they're upset after sharing a bathroom with a trans person, U.S. Olympic women's ice hockey team captain Hilary Knight leads her team to gold and plans to lead speed skater Brittany Bowe to the altar, and more international LGBTQ news reported this week by Nico Raquel and Ret (produced by Brian DeShazor). All this on the February 23, 2026 edition of This Way Out! Join our family of listener-donors today at thiswayout.org/donate/.

In his new book Shooting Up: A Memoir of Love, Loss and Addiction, Jonathan Tepper recounts growing up in Madrid's heroin epidemic as his missionary parents built a grassroots rehab network in one of Europe's hardest-hit neighborhoods. Surrounded by addicts, crime, and a generation devastated by HIV, he watched lives restored through faith and discipline—while also burying friends and even his own brother after a tragic accident. This is a stark, deeply personal account of addiction, redemption, and what sacrificial love looks like in the middle of cultural collapse. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

──────────────────────────────────────── 00:00:42:27 — Cybersecurity as Power, Not ProtectionCybersecurity is framed as a tool for centralized control and regime continuity rather than public safety, with Palantir cited as emblematic of surveillance-state architecture. ──────────────────────────────────────── 00:02:06:22 — Pam Bondi's Epstein Record ReexaminedQuestions resurface about Bondi's inaction on Epstein cases despite a public reputation for aggressively prosecuting trafficking crimes. ──────────────────────────────────────── 00:08:38:07 — Trump–Epstein Social Ties RevisitedPrior associations and evasive statements are revisited amid renewed scrutiny of elite political networks. ──────────────────────────────────────── 00:16:02:29 — From Ministry to Cold-Turkey Heroin RecoveryA missionary outreach in 1980s Madrid evolves into an international addiction recovery model emphasizing discipline, structure, and community over substitution therapy. ──────────────────────────────────────── 00:29:23:23 — Heroin, Shared Needles, and Spain's AIDS ExplosionIntravenous drug culture and prison conditions accelerate HIV transmission during one of Europe's worst heroin crises. ──────────────────────────────────────── 00:31:56:02 — Addiction as Spiritual and Social BreakdownRecovery is framed as rooted in restored relationships, accountability, and moral transformation rather than purely medical intervention. ──────────────────────────────────────── 00:58:25:07 — Palantir Hack and the “Backdoor State”Alleged breaches raise fears of embedded surveillance backdoors across government and corporate systems. ──────────────────────────────────────── 01:07:07:00 — Internet of Things as National Security LiabilityExpanding military and infrastructure interconnectivity is portrayed as multiplying systemic vulnerabilities rather than strengthening defense. ──────────────────────────────────────── 01:12:03:04 — Pentagon AI Expansion Despite Repeated BreachesVault 7, NSA hacks, and other incidents are cited as evidence that automation and AI integration are outpacing competence and safeguards. ──────────────────────────────────────── 01:17:22:01 — Offline Nuclear Systems vs. Cloud DefenseCold War air-gapped missile systems are contrasted with today's cloud-dependent defense architecture. ──────────────────────────────────────── 01:36:10:00 — Low-Tech Tools Defeat High-Tech DronesSimple heat shielding and optical tricks demonstrate asymmetric weaknesses in advanced surveillance and warfare technology. ──────────────────────────────────────── 01:44:29:12 — Autonomous Vehicle Ethics and Control HierarchiesAI-driven transportation raises unresolved questions about programmed value judgments, liability, and loss of human override authority. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

In his new book Shooting Up: A Memoir of Love, Loss and Addiction, Jonathan Tepper recounts growing up in Madrid's heroin epidemic as his missionary parents built a grassroots rehab network in one of Europe's hardest-hit neighborhoods. Surrounded by addicts, crime, and a generation devastated by HIV, he watched lives restored through faith and discipline—while also burying friends and even his own brother after a tragic accident. This is a stark, deeply personal account of addiction, redemption, and what sacrificial love looks like in the middle of cultural collapse. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

──────────────────────────────────────── 00:00:42:27 — Cybersecurity as Power, Not ProtectionCybersecurity is framed as a tool for centralized control and regime continuity rather than public safety, with Palantir cited as emblematic of surveillance-state architecture. ──────────────────────────────────────── 00:02:06:22 — Pam Bondi's Epstein Record ReexaminedQuestions resurface about Bondi's inaction on Epstein cases despite a public reputation for aggressively prosecuting trafficking crimes. ──────────────────────────────────────── 00:08:38:07 — Trump–Epstein Social Ties RevisitedPrior associations and evasive statements are revisited amid renewed scrutiny of elite political networks. ──────────────────────────────────────── 00:16:02:29 — From Ministry to Cold-Turkey Heroin RecoveryA missionary outreach in 1980s Madrid evolves into an international addiction recovery model emphasizing discipline, structure, and community over substitution therapy. ──────────────────────────────────────── 00:29:23:23 — Heroin, Shared Needles, and Spain's AIDS ExplosionIntravenous drug culture and prison conditions accelerate HIV transmission during one of Europe's worst heroin crises. ──────────────────────────────────────── 00:31:56:02 — Addiction as Spiritual and Social BreakdownRecovery is framed as rooted in restored relationships, accountability, and moral transformation rather than purely medical intervention. ──────────────────────────────────────── 00:58:25:07 — Palantir Hack and the “Backdoor State”Alleged breaches raise fears of embedded surveillance backdoors across government and corporate systems. ──────────────────────────────────────── 01:07:07:00 — Internet of Things as National Security LiabilityExpanding military and infrastructure interconnectivity is portrayed as multiplying systemic vulnerabilities rather than strengthening defense. ──────────────────────────────────────── 01:12:03:04 — Pentagon AI Expansion Despite Repeated BreachesVault 7, NSA hacks, and other incidents are cited as evidence that automation and AI integration are outpacing competence and safeguards. ──────────────────────────────────────── 01:17:22:01 — Offline Nuclear Systems vs. Cloud DefenseCold War air-gapped missile systems are contrasted with today's cloud-dependent defense architecture. ──────────────────────────────────────── 01:36:10:00 — Low-Tech Tools Defeat High-Tech DronesSimple heat shielding and optical tricks demonstrate asymmetric weaknesses in advanced surveillance and warfare technology. ──────────────────────────────────────── 01:44:29:12 — Autonomous Vehicle Ethics and Control HierarchiesAI-driven transportation raises unresolved questions about programmed value judgments, liability, and loss of human override authority. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

"He lies so much that he lies even when he just says, 'Good morning.'" Pablo's latest episode tells the previously untold story of how a former Miami Heat player and current DJ, Rony Seikaly, changed the perception of HIV forever by playing a single game of one-on-one, but Dan's more concerned with the fact that Pablo seems to be broadcasting to us from a can of some sort. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Tom opens this week's livestream with updates and announcements:He thanks the community for their continued support and invites listeners to help reach 100,000 followers on Facebook. If you haven't already, make sure you follow us on Facebook.Registration remains open for the New Biology Experience at Polyface Farm (June 2026). Tom encourages early sign-up while space is still available and reminds everyone that early bird pricing is still an option.New Biology Experience link here.This week's session centers around a core theme: separating what we actually observe from the stories we construct about what we think is happening.A thoughtful Q&A on:-What about HIV and hep C that people get from blood transfusions?-Does DNA testing detect consciousness in structured water?-How and when to use chlorine dioxide solution?-What about fever in children? When is this bad?-Is there such a thing as terminal or incurable illness?-Can you use food as medicine?-What do I think about biofield tuning?Throughout the session, Tom returns to a central question: “What do you see?” He challenges viewers to distinguish direct experience—what we see, feel, hear, smell, and taste—from the explanations layered on top of it.Support the showWebsites:https://drtomcowan.com/https://www.drcowansgarden.com/https://newbiologyclinic.com/https://newbiologycurriculum.com/Instagram: @TalkinTurkeywithTomFacebook: https://www.facebook.com/DrTomCowan/Bitchute: https://www.bitchute.com/channel/CivTSuEjw6Qp/YouTube: https://www.youtube.com/channel/UCzxdc2o0Q_XZIPwo07XCrNg

Early last year, a hundred researchers, clinicians and other experts on HIV discussed the development of an innovative vaccine that could prevent the disease. But just as the meeting was about to wrap up, the mood darkened. A new executive order signed by President Trump on Inauguration day had frozen all foreign aid, pending a review. Soon, DOGE would begin its decimation of USAID — and with it, this vaccine trial. That is – until the South African researchers came up with a new plan. Read more of freelance science reporter Ari Daniel's story here.Interested in more on the future of science? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this President's Day Radar Brief of The Wright Report, Bryan previews major stories unfolding at home and abroad, including troubling new details in the Nancy Guthrie kidnapping case in Tucson and a notable shift as Minnesota Democrats begin cooperating with ICE after weeks of defiance. Bryan also examines Hillary Clinton's surprising admission that open border policies "went too far," outlines President Trump's plan to build 92,000 new detention beds nationwide, and exposes how emotional media narratives often hide critical facts in high-profile immigration cases. He then turns to fresh revelations about partisan lawfare tied to the Trump investigations, new reporting on Jeffrey Epstein and coded communications, and a rare New York Times warning that America's marijuana experiment may be spiraling out of control. The episode closes with unsettling questions about whether advanced AI systems are beginning to think and react like humans, major signals from Europe that 100% solar and wind energy is failing, and encouraging medical breakthroughs in fibromyalgia treatment and immune health research worldwide.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: February 16 2026 Wright Report, Nancy Guthrie Tucson FBI DNA glove update, Minnesota Democrats cooperate ICE Tim Walz pivot, Hillary Clinton open borders admission Munich, Trump 92000 detention beds plan, Seamus Culleton visa overstay Ireland drug charges, JP Cooney Jack Smith prosecutor runs for Congress, Epstein pizza coded language email dump, New York Times marijuana psychosis warning, AI bot Scott Shambaugh code controversy, Macron Spain blackout solar wind failure, fibromyalgia duloxetine 120 mg study, gut microbiome HIV immune research

You've got junk, and we have info. The charming and hilarious researcher, professor, sex-positive health advocate, and author of the science book “Strange Bedfellows,” Dr. Ina Park, joins to talk about sores, symptoms, muffs, condoms, testing schedules, titillating vaccine developments, miracle medications, Brazilians, HIV magic, stepping out vs. opening up, toilet seats, antibiotics, new scientific shockers about bacterial vaginosis, crotch crickets, conservative obstructions, the secrets of Columbus, and most importantly how to stay horny, true to yourself, and safe. Whether you're monogamous, open, ace, or dating, she's giving the advice you need to communicate more openly and have more empathy for the health of friends and strangers. Visit Dr. Park's website and follow her on InstagramBuy her book, Strange Bedfellows: Adventures in the Science, History, and Surprising Secrets of STDs, on Bookshop.org or AmazonDonations went to the University of Alabama at Birmingham Dr. C. Kirk Avent Endowed Support Fund and the San Francisco City ClinicMore episode sources and linksOther episodes you may enjoy: Sexology (SEX), Urology (CROTCH PARTS), Phallology (PENISES), Gynecology (NETHER HEALTH), Epidemiology (DISEASES), Biological Anthropology (SEXY APES), Neuroendocrinology (SEX & GENDER), Venusology (VENUS), Carcinology (CRABS), Trichology (HAIR), Eschatology (THE APOCALYPSE)400+ Ologies episodes sorted by topicSmologies (short, classroom-safe) episodesSponsors of OlogiesTranscripts and bleeped episodesBecome a patron of Ologies for as little as a buck a monthOlogiesMerch.com has hats, shirts, hoodies, totes!Follow Ologies on Instagram and BlueskyFollow Alie Ward on Instagram and TikTokEditing by Mercedes Maitland of Maitland Audio Productions and Jake ChaffeeManaging Director: Susan HaleScheduling Producer: Noel DilworthTranscripts by Aveline Malek Website by Kelly R. DwyerTheme song by Nick Thorburn Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.